Want to join the conversation?
$ACOR said it will also obtain global rights to SYN120, an oral, 5-HT6/5-HT2A dual receptor antagonist for Parkinson's-related dementia, in Phase 2 development with support from the Michael J. Fox Foundation. In a Phase 2b clinical trial, tozadenant reduced average daily OFF time as an adjunct to treatment regimens including levodopa/carbidopa.
$SBUX launched its annual “Starbucks for Life” competition in the U.S. and Canada. The winner of the competition will receive a credit of one drink or food item per day for a duration of 30 years.
$T shares rose 1.8%, as a big boost for the S&P 500. The company said its new streaming television service DirectTV has so far exceeded expectations.
$TXMD flying high.. anyone here to catch..?
$CMG crashing. There seems to be nothing good to read about this company.